Beyond opioids: FDA-approved suzetrigine offers hope for acute pain management.
作者信息
Khan Aleeza, Irshad Maryam, Javed Zara, Naz Zahra, Fatima Mahnoor
机构信息
Department of Medicine, Nishtar Medical College, Nishtar Medical University, Multan, Pakistan.
Department of Medicine, Shaheed Ziaur Rahman Medical College, Rajshahi Medical University, Bogura, Bangladesh.
出版信息
Ann Med Surg (Lond). 2025 Jun 10;87(7):4023-4025. doi: 10.1097/MS9.0000000000003462. eCollection 2025 Jul.
Abstract
摘要
相似文献
1
Beyond opioids: FDA-approved suzetrigine offers hope for acute pain management.超越阿片类药物：美国食品药品监督管理局批准的舒泽曲明为急性疼痛管理带来希望。
Ann Med Surg (Lond). 2025 Jun 10;87(7):4023-4025. doi: 10.1097/MS9.0000000000003462. eCollection 2025 Jul.
2
Pharmacology Update: Suzetrigine: A Novel NaV1.8 Sodium Channel Inhibitor for Acute Pain Management.药理学最新进展：舒泽曲明：一种用于急性疼痛管理的新型Nav1.8钠通道抑制剂
Am J Hosp Palliat Care. 2025 Jul 2:10499091251353455. doi: 10.1177/10499091251353455.
3
Suzetrigine: A Novel Non-Opioid Analgesic for Acute Pain Management-A Review.舒泽曲明：一种用于急性疼痛管理的新型非阿片类镇痛药——综述
Drugs Drug Candidates. 2025 Sep;4(3). doi: 10.3390/ddc4030032. Epub 2025 Jul 4.
4
Suzetrigine, a Nonopioid Na V 1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials.舒泽曲明，一种用于治疗中重度急性疼痛的非阿片类钠通道蛋白1.8抑制剂：两项3期随机临床试验
Anesthesiology. 2025 Jun 1;142(6):1085-1099. doi: 10.1097/ALN.0000000000005460. Epub 2025 Mar 21.
5
Suzetrigine Approval Breaks a 25-Year Silence: A New Era in Non-Opioid Acute Pain Management.舒泽曲明获批打破25年沉寂：非阿片类急性疼痛管理新时代来临。
J Pain Res. 2025 Jun 6;18:2805-2808. doi: 10.2147/JPR.S526851. eCollection 2025.
6
Suzetrigine, a Non-Opioid Na1.8 Inhibitor With Broad Applicability for Moderate-to-Severe Acute Pain: A Phase 3 Single-Arm Study for Surgical or Non-Surgical Acute Pain.苏泽曲明，一种对中重度急性疼痛具有广泛适用性的非阿片类 Na1.8 抑制剂：一项针对手术或非手术急性疼痛的 3 期单臂研究。
J Pain Res. 2025 Mar 25;18:1569-1576. doi: 10.2147/JPR.S509144. eCollection 2025.
7
Suzetrigine (VX-548): Bidding goodbye to opioids: The latest oral non-opioid analgesic for acute pain.舒泽曲明（VX-548）：告别阿片类药物：最新的急性疼痛口服非阿片类镇痛药。
Saudi J Anaesth. 2025 Jul-Sep;19(3):384-386. doi: 10.4103/sja.sja_366_25. Epub 2025 Jun 16.
8
Suzetrigine: The first Nav1.8 inhibitor approved for the treatment of moderate to severe acute pain.舒泽曲明：首个获批用于治疗中度至重度急性疼痛的Nav1.8抑制剂。
Drug Discov Ther. 2025 Mar 6;19(1):80-82. doi: 10.5582/ddt.2025.01010. Epub 2025 Feb 27.
9
Suzetrigine: A novel selective sodium channel inhibitor for pain.
Am J Health Syst Pharm. 2025 Aug 18. doi: 10.1093/ajhp/zxaf219.
本文引用的文献
1
Personalised cancer vaccines and new regulatory struggles.
Lancet Oncol. 2025 Mar;26(3):265. doi: 10.1016/S1470-2045(25)00096-8.
2
Pharmacology and Mechanism of Action of Suzetrigine, a Potent and Selective Na1.8 Pain Signal Inhibitor for the Treatment of Moderate to Severe Pain.舒泽曲明的药理学及作用机制，一种用于治疗中重度疼痛的强效选择性Na1.8疼痛信号抑制剂
Pain Ther. 2025 Apr;14(2):655-674. doi: 10.1007/s40122-024-00697-0. Epub 2025 Jan 8.
3
Artificial intelligence alphafold model for molecular biology and drug discovery: a machine-learning-driven informatics investigation.人工智能 alphafold 模型在分子生物学和药物发现中的应用：基于机器学习的信息学研究。
Mol Cancer. 2024 Oct 5;23(1):223. doi: 10.1186/s12943-024-02140-6.
4
Opioid crisis: addiction, overprescription, and insufficient primary prevention.阿片类药物危机：成瘾、过度处方及初级预防不足。
Lancet Reg Health Am. 2023 Jul 12;23:100557. doi: 10.1016/j.lana.2023.100557. eCollection 2023 Jul.
5
The opioid epidemic: A worldwide exploratory study using the WHO pharmacovigilance database.阿片类药物流行：使用世界卫生组织药物警戒数据库进行的全球探索性研究。
Addiction. 2023 Apr;118(4):771-775. doi: 10.1111/add.16081. Epub 2022 Nov 22.
Zotero 插件